Introduction {#sec1}
============

Lopinavir and low-dose ritonavir are associated in a fixed-dose combination protease inhibitor therapy (LPV/RTV), indicated against human immunodeficiency virus infection (HIV) and acquired immune deficiency syndrome. The recent outbreak of severe acute respiratory syndrome coronavirus 2 infections causing coronavirus disease 2019 (Covid-19) has rekindled the interest in LPV/RTV, following preclinical studies.[@bib1] Although no benefit was observed with lopinavir-ritonavir treatment beyond standard care,[@bib2] other randomized controlled trials such as DisCoVeRy (NCT04315948) are currently enrolling. Like other antiretroviral (ARV) therapies, LPV/RTV has been previously associated with acute kidney injuries (AKI), even though; no systematic pharmacovigilance analysis was ever performed.

In this work, we first describe a small case-series of AKI associated with LPV/RTV in the course of Covid-19 treatment. Then, we performed a query in the World Health Organization (WHO) pharmacovigilance database, VigiBase®, and extracted all AKI associated with LPV/RTV. We then presented clinical characteristics of these events, and performed a comparison between HIV-, and Covid-19 indication in VigiBase®.

Methods {#sec2}
=======

Study design {#sec2.1}
------------

This work combines i) a case-series of all patients who presented AKI under LPV/RTV in our intensive care medicine department and ii) a worldwide pharmacovigilance observational case-control cross-sectional study focusing on AKI related to the usage of LPV/RTV. It relies on VigiBase®, a database encompassing 22 million individual case safety reports (ICSR) received worldwide.[@bib3] ICSRs include administrative information, drug involved, patient data, date of onset and nature of the outcome using the MedDRA (Medical Dictionary for Regulatory Activities) terms (currently version22.1). This work is ancillary to the Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 (CovidTox)([clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} identifier NCT04314817).

Analyses in VigiBase® {#sec2.2}
---------------------

To confirm whether LPV/RTV was significantly associated with AKI over-reporting in VigiBase®, we performed a disproportionality analysis also known as case--non-case analysis, following a methodology our group, like others, previously described.[@bib4] Included cases were ICSR with LPV/RTV suspected to be associated with AKI, flagged using the MedDRA preferred term level « acute kidney injury » from inception to May, 10^th^, 2020. The computed Bayesian disproportionality estimate was the information component (IC). The IC~025~ is the lower end of the 95% credibility interval for the IC. A positive value of the IC~025~ is significant.[@bib5] More information concerning calculation of the IC and IC~025~ are provided in **Online Supplementary Material**.

Continuous data were reported in median \[interquartile range\] due to their non-normal distribution and when applicable, group comparisons were performed using non-parametric tests. Time to onset (TTO) was computed as the time in days between the initiation of LPV/RTV and the date of AKI. Concurrent renal adverse events are detailed in **Online Supplementary material**. All data were available, otherwise specified.

Results {#sec3}
=======

Case-series of LPV/RTV associated with AKI in patients with Covid-19

We observed 8 cases of patients treated by LPV/RTV who presented AKI. They were all admitted for Covid-19, 5/8, 62.5% were men. They required intensive care with a median Sepsis-related Organ Failure Assessment (SOFA) of 7 \[5;10\], moreover, 7/8, 87.5% required vasopressor support agents. Median TTO was 1 \[0;2\] days. In these patients, proteinuria was observed in 6/8, 75% and hematuria in 4/8, 50%. Two patients required dialysis (see [Table](#tbl1){ref-type="table"} ).Table 1Clinical summary of patients treated with LPV/RTV for Covid-19 who presented AKIGenderAge (years)SOFAVasopressor agentKDIGODialysis requirementChronic kidney diseaseTime to onset (day)DeathProteinuriaHematuriaLactic acidosis**\#1**Male413Yes2YesNo3YesYesNoNo**\#2**Female7011Yes2NoNo0NoNoNoNo**\#3**Male819Yes3NoNo1YesYesYesNo**\#4**Female705Yes3NoNo0YesYesYesNo**\#5**Male549No3NoNo0NoYesYesNo**\#6**Male785Yes3YesNo0YesYesYesNo**\#7**Female554Yes2NoNo1NoYesNoNo**\#8**Male6312Yes2NoNo0NoNoYesNo[^1]

Analysis of cases of AKI-associated with LPV/RTV in VigiBase®

In VigiBase®, among 22,035,564 ICSR, there were 162 cases of AKI-associated with LPV/RTV, reported from 55 countries. Information component of the association LPV/RTV with AKI was found significant (IC=1.5 and IC~025~=1.3). First case was reported in 2001 and IC became significant in 2003. This year (2020) saw the highest number of events reported of the last 5-year-period, with 13 cases (see [Figure](#fig1){ref-type="fig"} ). Median age was 50 \[41;60\] years. Men represented 109/162, 67.3% of cases and women 45/162, 27.8% (unknown in 8/162, 4.9% cases). Main indication was HIV in 152/162, 93.8 %, and Covid-19 in 10/162, 6.2% patients. TTO was longer in HIV than in Covid-19 indication (185 \[17;526\] vs. 3 \[0;5\] days; p\<0.0001). Overall mortality (associated or not) after these AKI events was 28/162, 17.2% (no significant difference between Covid-19 and HIV indication (2/10, 20% vs. 22/152, 14.5%, p=0.81). LPV/RTV was the only incriminated drug in 23/162, 14.2% of cases (13/152, 8.6 % in HIV- versus 10/10 (all) in Covid-19 indication; p\<0.0001)(see **Supplementary Figure** for detail on drugs concurrently reported). In HIV-infected patients, co-reported renal adverse events were lactic acidosis (15/152, 10%) and Fanconi syndrome (12/152, 8%), with few proteinuria (2.7%) and hematuria (2.7%). Associated renal adverse events were not reported in Covid-19 patients in VigiBase®.Figure 1Evolution of reporting (panel A) and information component (IC) (panel B) of lopinavir-ritonavir-associated acute kidney injury in the World Health Organization pharmacovigilance database, VigiBase®, as of May, 2020.

Discussion {#sec4}
==========

Until 2020, LPV/RTV was mainly indicated in HIV-infected patients. Acute interstitial nephritis (AIN) has been described in these patients. Drug-mediated AIN is identified as a cause in a majority of case, after extended use and often presents as proximal tubular injury.[@bib6] In HIV-infected patients, drugs, commonly associated with AIN, are non-steroidal anti-inflammatory drugs, sulfamethoxazole/trimethoprim and ARV therapy. ARV-related nephrotoxicity is mainly caused by tenofovir with Fanconi syndrome. Moreover, it is often associated with low-dose RTV, decreasing renal clearance of tenofovir. In VigiBase®, in patients with HIV, Fanconi syndrome was described in 12% of AKI events, which may be due to co-treatment with other ARV therapy in 90% of patients (mostly tenofovir and emtricitabine). Lactic acidosis was coreported in 10%, partly due to mitochondrial cytopathy, like those under stavudine and didanosine.

During the Covid-19 pandemic, AKI incidence ranged from 5% to 29% depending on patients' severity with coreported proteinuria and hematuria.[@bib7] The virus targets the angiotensin-converting enzyme II (ACE2). This enzyme is expressed in the lungs, but has been reported expressed in the kidney, confirmed on post-mortem biopsies with viral inclusion in tubular epithelial cells and podocytes. Tubular damage through direct cytotoxicity or by immune-mediates tubule pathogenesis may be involved in Covid-19-related AKI.[@bib8]

These elements may explain the differences we observed when comparing LPV/RTV-associated AKI in HIV- and Covid-19 indications. In our case series, patients were severe with high admission SOFA and most needed vasopressor support. Moreover, TTO was much shorter than that of previously described AKI in HIV indication, which points towards the role of sepsis related to Covid-19, which may be, in this case, a major confounding element. Aggravating factors such as low perfusion due to vasoconstrictive agents, hypoxia, rhabdomyolysis, inflammation due to cytokine release syndrome, and immune-mediated tubulopathy with CD68+ macrophage and C5b-9 deposition, may be intertwined, on top of tubular damage observed in Covid-19.[@bib9] Following observation that LPV/RTV did not benefit our patients, and was associated with AKI, we did not pursue this treatment in Covid-19 patients admitted in our ward.

We acknowledge several limitations, mostly under-reporting, associated with halo bias and lack of information. The likelihood of a causal relationship is not the same in all reports. Missing data is another limitation in pharmacovigilance database extractions. Analyzes were performed on over-reporting, and not assessment of true relative risk, which would require the absolute number of exposed patients (missing here). It must be noted that disproportionality analysis allows to focus the attention of clinical physicians, and to assess plausibility of the incrimination of a drug towards a singular adverse event, i.e. LPV/RTV with AKI.

Conclusion {#sec5}
==========

AKI-associated with LPV/RTV was previously reported in the WHO pharmacovigilance database for HIV indication and Covid-19 saw a rise in these reports. As Covid-19, may inherently cause AKI, the possible synergistic effects of LPV/RTV and Covid-19 on AKI need to be further investigated.

**Disclosure Statement.** The supplied data from VigiBase® come from various sources. The likelihood of a causal relationship is not the same in all reports. The information does not represent the opinion of WHO. The authors have nothing to disclose related to this study. The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedure at <http://www.vigiaccess.org/>.

Furthermore, all eight cases described were reported in the French pharmacovigilance database (but were not implemented in VigiBase, yet), and description of these drug-associated adverse events fall under relevant authorizations.

Supplementary Material {#appsec1}
======================

[^1]: Abbreviations: KDIGO: Kidney Disease Improving Global Outcomes classification, SOFA: Sequential Organ Failure Assessment score
